Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02133248 · ClinicalTrials.gov registry record
Identification of Donor Specific B Cells and Antibody Mediated Rejection
A clinical trial, sponsored by University of Wisconsin, Madison.
- Terminated
- Registry status
- 86
- Enrollment target
NCT02133248 is a clinical trial that was terminated before completion, run by University of Wisconsin, Madison. The registered enrollment target is 86 participants.
The verdict
NCT02133248 was terminated before completion, sponsored by University of Wisconsin, Madison.
- TERMINATED
- Registry status
- 86 participants
- Enrollment target
Study Summary
Many people who are on the wait list for a kidney transplant have harmful antibodies, called donor specific antibodies (DSA), which will attack foreign tissue such as the transplanted organ. These people are considered to be"sensitized". Prior to receiving a kidney, these patients undergo desensitization treatments to remove these harmful antibodies. Levels of DSA are measured after desensitization, but the cells that produce the DSA, donor specific B cells (DSB), have not generally been measured. Additionally, if a person experiences chronic rejection due to antibodies they are also desensitized, but only the DSA are measured. This study will measure the DSA and, using new techniques, the DSB in two study groups: those who are receiving an organ and those experiencing chronic antibody mediated rejection after receiving an organ. The hypothesis is people with higher levels of DSB after desensitization are more likely to develop antibody mediated rejection.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2014-06-05 |
| Est. Completion | 2021-11-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02133248
The ClinicalTrials.gov registry entry for NCT02133248 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02133248 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02133248 about?
NCT02133248 is a clinical study titled "Identification of Donor Specific B Cells and Antibody Mediated Rejection". Many people who are on the wait list for a kidney transplant have harmful antibodies, called donor specific antibodies (DSA), which will attack foreign tissue such as the transplanted organ. These people are considered to be"sensitized". Prior to receiving a kidney, these patients undergo desensitiz...
What is the current status of trial NCT02133248?
This trial is currently terminated. The enrollment target is 86 participants. The study started on 2014-06-05. Estimated completion is 2021-11-17.
Who is sponsoring clinical trial NCT02133248?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.